131 related articles for article (PubMed ID: 32329851)
1. ANXA3 deletion inhibits the resistance of lung cancer cells to oxaliplatin.
Jin YF; Huang YT; Chen PF
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3741-3748. PubMed ID: 32329851
[TBL] [Abstract][Full Text] [Related]
2. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells.
Wang L; Li X; Ren Y; Geng H; Zhang Q; Cao L; Meng Z; Wu X; Xu M; Xu K
Cancer Sci; 2019 May; 110(5):1609-1620. PubMed ID: 30868675
[TBL] [Abstract][Full Text] [Related]
4. Silencing of ANXA3 expression by RNA interference inhibits the proliferation and invasion of breast cancer cells.
Zhou T; Li Y; Yang L; Liu L; Ju Y; Li C
Oncol Rep; 2017 Jan; 37(1):388-398. PubMed ID: 27878264
[TBL] [Abstract][Full Text] [Related]
5. Annexin A3 Knockdown Suppresses Lung Adenocarcinoma.
Liu YF; Liu QQ; Zhang YH; Qiu JH
Anal Cell Pathol (Amst); 2016; 2016():4131403. PubMed ID: 27995049
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of annexin A3 inhibits tumor metastasis and decreases drug resistance in breast cancer.
Du R; Liu B; Zhou L; Wang D; He X; Xu X; Zhang L; Niu C; Liu S
Cell Death Dis; 2018 Jan; 9(2):126. PubMed ID: 29374148
[TBL] [Abstract][Full Text] [Related]
7. MiR-145 changes sensitivity of non-small cell lung cancer to gefitinib through targeting ADAM19.
Wang Y; Lian YM; Ge CY
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5831-5839. PubMed ID: 31298334
[TBL] [Abstract][Full Text] [Related]
8. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
9. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
[TBL] [Abstract][Full Text] [Related]
10. Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma.
Pan QZ; Pan K; Weng DS; Zhao JJ; Zhang XF; Wang DD; Lv L; Jiang SS; Zheng HX; Xia JC
Mol Carcinog; 2015 Aug; 54(8):598-607. PubMed ID: 24375474
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Suppressing Effect of Silencing of Annexin A3 Expression in Breast Cancer.
Kim JY; Jung EJ; Park HJ; Lee JH; Song EJ; Kwag SJ; Park JH; Park T; Jeong SH; Jeong CY; Ju YT; Lee YJ; Hong SC
Clin Breast Cancer; 2018 Aug; 18(4):e713-e719. PubMed ID: 29217453
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA SNHG15 indicates poor prognosis of non-small cell lung cancer and promotes cell proliferation and invasion.
Dong YZ; Meng XM; Li GS
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2671-2679. PubMed ID: 29771418
[TBL] [Abstract][Full Text] [Related]
14. GLIPR1 modulates the response of cisplatin-resistant human lung cancer cells to cisplatin.
Gong X; Liu J; Zhang D; Yang D; Min Z; Wen X; Wang G; Li H; Song Y; Bai C; Li J; Zhou J
PLoS One; 2017; 12(8):e0182410. PubMed ID: 28771580
[TBL] [Abstract][Full Text] [Related]
15. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer.
Song W; Qian Y; Zhang MH; Wang H; Wen X; Yang XZ; Dai WJ
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3049-3061. PubMed ID: 32271422
[TBL] [Abstract][Full Text] [Related]
16. Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS.
Zeng X; Wang S; Gui P; Wu H; Li Z
Mol Med Rep; 2019 Sep; 20(3):2583-2590. PubMed ID: 31524248
[TBL] [Abstract][Full Text] [Related]
17. [Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells].
Zhang MC; Hu CP; Chen Q
Zhonghua Zhong Liu Za Zhi; 2006 Jun; 28(6):408-12. PubMed ID: 17152483
[TBL] [Abstract][Full Text] [Related]
18. [The roles of holothurian glycosaminoglycan combined with cisplatin on proliferation and chemotherapeutic response in A549 human lung adenocarcinoma cell].
Jin Q; Zhu XH; Lin CZ; Zhang H; Cao YW; Ding XQ; Lyu ZH
Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):252-257. PubMed ID: 29730910
[No Abstract] [Full Text] [Related]
19. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
Gong J; He L; Ma J; Zhang J; Wang L; Wang J
J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
[TBL] [Abstract][Full Text] [Related]
20. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
